Diamyd Medical AB (FRA:DMN) YoY EBITDA Growth: -111.11% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
40 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB YoY EBITDA Growth?

Diamyd Medical AB FRA:DMN -0.69% 40 YoY EBITDA Growth is -111.11% as of May. 2026. GuruFocus rates FRA:DMN with a GF Score™ of 40/100 and a GF Value™ of €0.07 (Fairly Valued). The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Diamyd Medical AB's YoY EBITDA Growth for the quarter that ended in May. 2026 was -111.11%.

Diamyd Medical AB's EBITDA per Share for the three months ended in May. 2026 was €-0.08.

Diamyd Medical AB YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB YoY EBITDA Growth Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 500.00 -241.67 -0.84 -7.50 -0.78

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.88 24.32 -14.81 -10.81 -111.11
FRA:DMN
40GF Score
Diamyd Medical AB FRA:DMN
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Diamyd Medical AB's YoY EBITDA Growth for the fiscal year that ended in Aug. 2025 is calculated as:

YoY EBITDA Growth (A: Aug. 2025 )
=(EBITDA per Share (A: Aug. 2025 )-EBITDA per Share (A: Aug. 2024 ))/ | EBITDA per Share (A: Aug. 2024 ) |
=(-0.13--0.129)/ | -0.129 |
=-0.78 %

Diamyd Medical AB's YoY EBITDA Growth for the quarter that ended in May. 2026 is calculated as:

YoY EBITDA Growth (Q: May. 2026 )
=(EBITDA per Share (Q: May. 2026 )-EBITDA per Share (Q: May. 2025 )) / | EBITDA per Share (Q: May. 2025 )) |
=(-0.076--0.036)/ | -0.036 |
=-111.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -111.11% mean?
Diamyd Medical AB (FRA:DMN) has a YoY EBITDA Growth of -111.11% as of May. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Diamyd Medical AB and its competitors.
Is Diamyd Medical AB's YoY EBITDA Growth too high?
Diamyd Medical AB's current YoY EBITDA Growth is -111.11%. Overall, Diamyd Medical AB has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's YoY EBITDA Growth compare to VRTX and REGN?
Diamyd Medical AB's YoY EBITDA Growth of -111.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Diamyd Medical AB and its competitors. Diamyd Medical AB's current YoY EBITDA Growth is -111.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (FRA:DMN) is currently considered Fairly Valued. The stock's GF Value™ is €0.07, compared to a current price of €0.07 — trading 3.4% above its estimated fair value. The current YoY EBITDA Growth is -111.11%. Diamyd Medical AB's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Diamyd Medical AB (FRA:DMN), the current YoY EBITDA Growth is -111.11% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued. The current stock price of €0.07 is trading 3.4% above its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • YoY EBITDA Growth: -111.11%
  • GF Value™: €0.07 vs. price of €0.07 (3.4% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
40GF Score

Get the complete analysis for FRA:DMN

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value